Terms: = Gastric cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Clinical Outcome
3 results:
1. Correlation of COX-2 and k-ras expression to clinical outcome in gastric cancer.
Li M; Liu W; Zhu YF; Chen YL; Zhang BZ; Wang R
Acta Oncol; 2006; 45(8):1115-9. PubMed ID: 17118848
[TBL] [Abstract] [Full Text] [Related]
2. DNA aneuploidy and high proliferative activity but not k-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: results of a 5-year Gruppo Oncologico dell'Italia Meridonale (GDIM) prospective study.
Russo A; Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Latteri F; Valerio MR; Pantuso G; Morello V; Dardanoni G; Latteri MA; Colucci G; Tomasino RM; Gebbia N
Cancer; 2001 Jul; 92(2):294-302. PubMed ID: 11466682
[TBL] [Abstract] [Full Text] [Related]
3. P21 protein expression and ras-oncogene mutations in gastric carcinoma: correlation with clinical data.
Kasper HU; Schneider-Stock R; Mellin W; Roessner A
Int J Oncol; 1998 Jan; 12(1):69-74. PubMed ID: 9454888
[TBL] [Abstract] [Full Text] [Related]
